• Facebook
  • X
Phone: (843) 449-1010 | 823 82nd Parkway, Suite B, Myrtle Beach, SC 29572
Carolina Urologic Research Center - Myrtle Beach, SC
  • Home
  • About Us
  • Staff
    • Clinical Investigators
    • Clinical Staff
    • Associated Providers
  • Current Trials
    • Bladder Cancer
    • Prostate Cancer
    • Other
    • Patient Trials Form
  • Patient Info
    • Patient Info
    • Helpful Links
    • Q&A About Clinical Trials
  • Testimonials
  • In The News
    • In The News
  • Contact
  • Search
  • Menu Menu
Blog - Latest News
You are here: Home1 / Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility. By Dr. Neal Shore2 / 3.27-AbirateroneAcetate

3.27-AbirateroneAcetate

March 27, 2017/by CURC

Share this entry
  • Share on Facebook
  • Share on X
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
/wp-content/uploads/logo-1.png 0 0 CURC /wp-content/uploads/logo-1.png CURC2017-03-27 08:36:542017-03-27 08:36:543.27-AbirateroneAcetate

Current Happenings

  • Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
  • START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center
  • Final Version: Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
  • The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer
  • Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
  • Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
  • Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
  • Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now

Archives

Contact

Carolina Urologic Research Center
823 82nd Parkway, Suite B
Myrtle Beach, SC 29572

Phone: (843) 839-1679
Fax: (843) 286-0119

Email:
info@curcmb.com

Directions

Recent Happenings

  • Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
  • START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center
  • Final Version: Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
  • The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer

Our Affiliates

©2025 Carolina Urologic Research Center, LLC | All Rights Reserved | Site Design by Studio303, Inc.
  • Facebook
  • X
Scroll to top